Molecular Imaging and Precision Medicine in Head and Neck Cancer

Esther Mena; Shwetha Thippsandra; Anusha Yanamadala; Siddaling Redy; Puskar Pattanayak; Rathan M Subramaniam

doi:10.1016/j.cpet.2016.08.009

Molecular Imaging and Precision Medicine in Head and Neck Cancer

PET Clin. 2017 Jan;12(1):7-25. doi: 10.1016/j.cpet.2016.08.009. Epub 2016 Oct 5.

Authors

Esther Mena¹, Shwetha Thippsandra¹, Anusha Yanamadala¹, Siddaling Redy¹, Puskar Pattanayak¹, Rathan M Subramaniam²

Affiliations

¹ Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Johns Hopkins University, 601 North Caroline Street, Baltimore, MD 21287, USA.
² Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins School of Medicine, Johns Hopkins University, 601 North Caroline Street, Baltimore, MD 21287, USA; Department of Radiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8896, USA; Department of Clinical Sciences, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9096, USA; Department of Biomedical Engineering, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX, 75390-8896, USA; Advanced Imaging Research Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX, 75390-8896, USA. Electronic address: rathan.subramaniam@UTsouthwestern.edu.

PMID: 27863568
DOI: 10.1016/j.cpet.2016.08.009

Abstract

The concept of using tumor genomic profiling information has revolutionized personalized cancer treatment. Head and neck (HN) cancer management is being influenced by recent discoveries of activating mutations in epidermal growth factor receptor and related targeted therapies with tyrosine kinase inhibitors, targeted therapies for Kristen Rat Sarcoma, and MET proto-oncogenes. Molecular imaging using PET plays an important role in assessing the biologic behavior of HN cancer with the goal of delivering individualized cancer treatment. This review summarizes recent genomic discoveries in HN cancer and their implications for functional PET imaging in assessing response to targeted therapies, and drug resistance mechanisms.

Keywords: Head and neck cancer; Molecular imaging; Targeted therapy; Tumor genetic profiling.

Publication types

Review

MeSH terms

Biomarkers, Tumor
Drug Resistance, Neoplasm
Fluorodeoxyglucose F18
Genomics
Head and Neck Neoplasms / diagnostic imaging*
Head and Neck Neoplasms / genetics
Head and Neck Neoplasms / therapy*
Humans
Molecular Imaging*
Molecular Targeted Therapy
Positron Emission Tomography Computed Tomography
Positron-Emission Tomography*
Precision Medicine*
Prognosis
Radiopharmaceuticals

Substances

Biomarkers, Tumor
Radiopharmaceuticals
Fluorodeoxyglucose F18